Carcinoid Syndrome: Updates and Review of Current Therapy.
Opinion Statement: Carcinoid syndrome (CS) is a complex disorder caused by functional neuroendocrine tumors (NETs). This debilitating disease is characterized by hyper-secretion of biologically active substances eliciting major hormonal symptoms burden and fibrotic changes that are often challenging...
| Publicado en: | Current Treatment Options in Oncology Vol. 20; no. 9 |
|---|---|
| Autores principales: | , , , |
| Formato: | review tables/charts Journal Article |
| Publicado: |
Springer Nature
Sep2019
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=137769580&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 137769580 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 15272729 3KHC jtl: Current Treatment Options in Oncology issn: 15272729 maglogo: N pubinfo: dt: Sep2019 vid: 20 iid: 9 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 137769580 137769580 NLM31286272 137769580 10.1007/s11864-019-0671-0 NLM31286272 137769580 ppct: 1 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: Carcinoid Syndrome: Updates and Review of Current Therapy. aug: au: Oleinikov, Kira Avniel-Polak, Shani Gross, David J. Grozinsky-Glasberg, Simona affil: Neuroendocrine Tumor Unit, ENETS Center of Excellence, Endocrinology and Metabolism Department, Division of Medicine, Hadassah-Hebrew University Medical Center, P.O.B. 12000, 91120, Jerusalem, Israel sug: subj: Malignant Carcinoid Syndrome Therapy Malignant Carcinoid Syndrome Diagnosis Combined Modality Therapy Methods Disease Management Algorithms Malignant Carcinoid Syndrome Etiology Clinical Trials Malignant Carcinoid Syndrome Epidemiology Treatment Outcomes Clinical Assessment Tools Scales ab: Opinion Statement: Carcinoid syndrome (CS) is a complex disorder caused by functional neuroendocrine tumors (NETs). This debilitating disease is characterized by hyper-secretion of biologically active substances eliciting major hormonal symptoms burden and fibrotic changes that are often challenging for management. There have been a number of insights that have substantially advanced treatments since the introduction of somatostatin analogs (SSAs). Second-line treatments are needed in a substantial proportion of patients with advanced disease that have uncontrolled hormone secretion on the highest labeled doses of SSAs. International guidelines suggest several available options including dose escalation of SSAs, interferon alpha, everolimus, radionuclide therapy, liver-directed therapies, and the novel tryptophan hydroxylase 1 inhibitor, telotristat ethyl. The clear preference of one second-line therapy over the other is not stated since their relative and long-term efficacy are largely unknown, and standardized approach of hormonal response assessment is lacking in the literature. In the clinical setting, the treatment of CS is guided in conjunction with patients' performance status, tumor origin, grade, stage, and growth rate, with regard to both anti-hormonal, as well as anti-proliferative effect. There is an unmet need for further well-designed randomized placebo-controlled and head-to-head studies that systematically assess CS symptom control and biochemical response following a specific intervention. pubtype: Academic Journal doctype: review tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|